# OnCo record avutometinib-defactinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/avutometinib-defactinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "avutometinib-defactinib" ;
  schema:name "Avutometinib + defactinib"@en ;
  schema:alternateName "Avutometinib"@en, "Defactinib"@en, "Avutometinib and defactinib"@en, "Avmapki Fakzynja Co-Pack" ;
  schema:description "Avutometinib plus defactinib is the first treatment approved specifically for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway."@en ;
  schema:url <https://onco.cc/drugs/avutometinib-defactinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Avutometinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule RAF/MEK clamp + FAK inhibitor" ;
  onco:approval "US 2025: KRAS-mutated recurrent low-grade serous ovarian cancer after prior systemic therapy (accelerated)" ;
  onco:acceleratedApproval "US 2025-05-08: Treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/fak/> ;
  onco:companies <https://onco.cc/companies/verastem/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/lgsoc/> ;
  onco:trials <https://onco.cc/trials/ramp-201/> .